Wednesday, 10 September 2014

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim Alliance

Incretin-Based Drugs and the Risk of Congestive Heart Failure

In our population-based study, incretin-based drug use was not associated with an increased risk of CHF among patients with type 2 diabetes (Diabetes Care)

Ethnicity-specific obesity cut-points in the development of Type 2 diabetes – a prospective study including three ethnic groups in the United Kingdom

In prospective analyses, British South Asians and African-Caribbeans had equivalent diabetes incidence rates at substantially lower obesity levels than the conventional European cut-points (Diabetic Medicine)

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

Use of statins before diagnosis of incident diabetes was not associated with an increased risk of microvascular disease. Whether statins are protective against some forms of microvascular disease—a possibility raised by these data—will need to be addressed in other studies (The Lancet Diabetes & Endocrinology)

Increase in the pharmacological management of Type 2 diabetes with pay-for-performance in primary care in the UK

We conclude that a greater proportion of people with newly diagnosed diabetes are being initiated on medication within 1 and 2 years of diagnosis as a result of the introduction of financial incentives for tight glycaemic control (Diabetic Medicine)

No comments:

Post a Comment